Pharmaceuticals

Sanofi's latest FDA nod for Tzield isn't just a new drug approval; it's a strategic shift from symptom management to disease modification in Type 1 Diabetes.

Atossa Therapeutics secures a crucial capital lifeline. We dissect the deal, its impact on a promising cancer drug, and what it reveals about biotech funding today.

U.S. hospitals waste billions in usable medication each year. A new partnership shows how AI and a digital marketplace can plug the leak, a crucial move in an era of drug shortages.

A silent barrier in diabetes care, 'clinical inertia,' leaves patients at risk. New research shows how empowering pharmacists with targeted education can turn the tide.

Promising clinical trial results offer hope for cancer patients at risk of permanent, treatment-induced hearing loss, a devastating and common trade-off.

A landmark deal for CEL-SCI’s cancer drug Multikine in Saudi Arabia isn't just about a new market; it’s a case study in national ambition and biotech finance.

Kymera Therapeutics reports promising data for KT-621, a first-in-class oral drug that removes a key inflammatory protein, not just block it.

Jazz Pharma's lung cancer drug Zepzelca fails a key trial, raising regulatory questions. Yet its strength in another setting reveals a complex drug development system.

MBX Biosciences' new one-year data for canvuparatide isn't just a clinical win; it's a calculated move to dominate a billion-dollar market left vacant.

Novartis unveils groundbreaking Phase III data for Rhapsido, offering hope as the first potential targeted therapy for 29 million chronic hive sufferers.

With a new CMO, Get A Drip is capitalizing on the longevity trend. But as it expands, it faces questions on scientific rigor and regulatory oversight.

Elixiron's enrupatinib shows promise in targeting neuroinflammation, with early data suggesting cognitive benefits and a new biomarker-guided path for therapy.

For decades, patients with a rare autoimmune anemia faced a cycle of steroids and relapse. New data on a targeted therapy may finally offer a durable solution.

Xeris Biopharma secures a new patent for its rare disease drug KEVEYIS until 2039, a strategic move to fend off generic competition and lock in revenue.

With a record-breaking IPO and over $1.2 billion raised this year, Parabilis Medicines is attacking diseases once thought untouchable. But can its Helicon platform deliver?

Leveraged finance titans turned a personal fight into a philanthropic powerhouse, raising a record $4.3M to fund the science that’s turning the tide on melanoma.

With over 55,000 on waitlists for the UK's first oral weight-loss pill, the market is set to explode. But strict rules and high hopes face a reality check.

Amedea Pharma's Medical Innovation Olympics isn't just a contest; it's a data-driven crucible for new treatments, with longevity medicine taking center stage.

An Arizona nonprofit’s innovative sweepstakes, driven by a personal mission, is accelerating gene therapy for childhood blindness. A new model for impact.

A projected 14.9% CAGR signals a gold rush in Alzheimer's agitation treatment. New, safer drugs are replacing risky antipsychotics, offering hope to millions.